Multivalent Monospecific Antibody Assembly via Segmented scFv
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to developing multispecific and multivalent therapeutic compositions, such as antibodies, face challenges in retaining typical Ig function, production yield, valency, simultaneous target recognition, and bioavailability, limiting their clinical potential for treating complex disorders like cancer and autoimmune diseases.
Innovation Solution
The development of multivalent and monovalent multispecific compositions using the ZYBODY platform, which generates synergistic biological activity by binding to multiple targets, including those associated with cancer, immune system disorders, and other diseases, utilizing modular recognition domains (MRDs) that can be linked to antibodies to enhance binding capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional bispecific antibodies are prepared by chemically linking two different monoclonal antibodies or by fusing hybridoma cell lines, then multispecific binding capability is achieved, but production complexity and cost increase significantly
Solution Approach 1:
The patent segments the antibody structure into separate single-chain variable fragments (scFv) that can be independently expressed and then assembled. This segmentation allows each binding domain to be produced separately in standard mammalian cell lines, avoiding the complexity of hybridoma fusion while maintaining multispecific binding capability through controlled assembly of the scFv fragments.
2Productivity
If alternative scaffolds such as VASP polypeptides, Affibodies, or DARPins are used to generate multispecific molecules, then production yield and purity improve, but retention of typical Ig function (half-life, effector function) deteriorates
Solution Approach 1:
The patent merges the advantages of alternative scaffolds with traditional Ig structures by using scFv fragments that can be assembled into formats retaining Ig Fc regions. This combination maintains the high production yield and purity of recombinant expression while preserving critical Ig functions including half-life through Fc-mediated recycling and effector functions through FcγR binding.
Solution Approach 2:
The patent creates composite antibody structures combining scFv binding domains with Ig Fc constant regions. This composite design integrates the production advantages of recombinant scFv expression with the functional advantages of intact Ig structures, achieving both high productivity and reliable Ig function retention.
3Reliability
If multivalent multisspecific compositions are designed to bind multiple targets simultaneously, then therapeutic efficacy improves, but molecular complexity and difficulty of manufacturing increase
Solution Approach 1:
The patent creates universal scFv assembly platforms where standardized scFv fragments can be combined in different configurations to produce various multivalent multispecific compositions. This universal approach allows the same manufacturing pipeline to produce different therapeutic variants by simply changing which scFv fragments are assembled together, significantly easing manufacturing complexity while maintaining the ability to achieve dramatic synergistic biological activity.
Data Source
AI summary
Compositions containing multivalent and monovalent multispecific complexes having scaffolds such as antibodies that support such binding functionalities are described. The use of and methods of compositions containing multivalent and monovalent multispecific complexes having scaffolds, such as antibodies, that support such binding functionalities are also described.